News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
722,302 Results
Type
Article (40944)
Company Profile (267)
Press Release (681080)
Multimedia
Podcasts (81)
Webinars (17)
Section
Business (204692)
Career Advice (2026)
Deals (35537)
Drug Delivery (111)
Drug Development (81390)
Employer Resources (173)
FDA (16426)
Job Trends (14947)
News (346442)
Policy (32733)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2571)
Accelerated approval (34)
Adcomms (24)
Allergies (144)
Alliances (49581)
ALS (170)
Alzheimer's disease (1676)
Antibody-drug conjugate (ADC) (314)
Approvals (16695)
Artificial intelligence (520)
Autoimmune disease (159)
Automation (42)
Bankruptcy (361)
Best Places to Work (11636)
BIOSECURE Act (20)
Biosimilars (192)
Biotechnology (174)
Bladder cancer (160)
Brain cancer (57)
Breast cancer (645)
Cancer (4857)
Cardiovascular disease (406)
Career advice (1711)
Career pathing (36)
CAR-T (283)
CDC (46)
Celiac Disease (2)
Cell therapy (749)
Cervical cancer (36)
Clinical research (69621)
Collaboration (1718)
Company closure (4)
Compensation (1172)
Complete response letters (57)
COVID-19 (2714)
CRISPR (93)
C-suite (863)
Cystic fibrosis (143)
Data (6296)
Decentralized trials (2)
Denatured (25)
Depression (135)
Diabetes (504)
Diagnostics (6711)
Digital health (49)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (255)
Drug pricing (184)
Drug shortages (28)
Duchenne muscular dystrophy (233)
Earnings (90263)
Editorial (58)
Employer branding (21)
Employer resources (152)
Events (117417)
Executive appointments (981)
FDA (19572)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (11)
Frontotemporal dementia (23)
Funding (1480)
Gene editing (199)
Generative AI (44)
Gene therapy (597)
GLP-1 (967)
Government (4667)
Grass and pollen (6)
Guidances (384)
Healthcare (18882)
HIV (62)
Huntington's disease (45)
IgA nephropathy (84)
Immunology and inflammation (254)
Immuno-oncology (60)
Indications (118)
Infectious disease (2990)
Inflammatory bowel disease (194)
Inflation Reduction Act (14)
Influenza (119)
Intellectual property (254)
Interviews (316)
IPO (16643)
IRA (50)
Job creations (3643)
Job search strategy (1429)
JPM (57)
Kidney cancer (16)
Labor market (86)
Layoffs (547)
Leadership (32)
Legal (7952)
Liver cancer (91)
Longevity (15)
Lung cancer (657)
Lymphoma (382)
Machine learning (42)
Management (59)
Manufacturing (808)
MASH (164)
Medical device (13781)
Medtech (13837)
Mergers & acquisitions (19971)
Metabolic disorders (1274)
Multiple sclerosis (164)
NASH (16)
Neurodegenerative disease (321)
Neuropsychiatric disorders (89)
Neuroscience (2922)
Neurotech (1)
NextGen: Class of 2026 (6520)
Non-profit (4515)
Now hiring (68)
Obesity (598)
Opinion (263)
Ovarian cancer (167)
Pain (199)
Pancreatic cancer (230)
Parkinson's disease (284)
Partnered (33)
Patents (507)
Patient recruitment (497)
Peanut (57)
People (58924)
Pharmaceutical (62)
Pharmacy benefit managers (29)
Phase 1 (21703)
Phase 2 (30640)
Phase 3 (22827)
Pipeline (5437)
Policy (287)
Postmarket research (2564)
Preclinical (9202)
Press Release (64)
Prostate cancer (240)
Psychedelics (48)
Radiopharmaceuticals (283)
Rare diseases (846)
Real estate (5956)
Recruiting (70)
Regulatory (24550)
Reports (53)
Research institute (2391)
Resumes & cover letters (352)
Rett syndrome (27)
RNA editing (16)
RSV (81)
Schizophrenia (148)
Series A (240)
Series B (191)
Service/supplier (11)
Sickle cell disease (97)
Special edition (22)
Spinal muscular atrophy (157)
Sponsored (42)
Startups (3615)
State (2)
Stomach cancer (18)
Supply chain (105)
Tariffs (84)
The Weekly (54)
Vaccines (1013)
Venture capital (89)
Weight loss (381)
Women's health (93)
Worklife (18)
Date
Today (46)
Last 7 days (564)
Last 30 days (2324)
Last 365 days (29745)
2026 (3983)
2025 (30173)
2024 (35219)
2023 (40075)
2022 (51175)
2021 (55712)
2020 (54084)
2019 (46538)
2018 (35019)
2017 (32116)
2016 (31488)
2015 (37561)
2014 (31327)
2013 (26346)
2012 (28571)
2011 (29265)
2010 (27328)
Location
Africa (738)
Alabama (84)
Alaska (7)
Arizona (311)
Arkansas (13)
Asia (39246)
Australia (6417)
California (11394)
Canada (3318)
China (1103)
Colorado (480)
Connecticut (483)
Delaware (341)
Europe (84628)
Florida (1710)
Georgia (361)
Hawaii (3)
Idaho (61)
Illinois (871)
India (69)
Indiana (527)
Iowa (22)
Japan (436)
Kansas (127)
Kentucky (40)
Louisiana (26)
Maine (72)
Maryland (1394)
Massachusetts (8154)
Michigan (327)
Minnesota (631)
Mississippi (5)
Missouri (128)
Montana (32)
Nebraska (28)
Nevada (122)
New Hampshire (79)
New Jersey (3026)
New Mexico (28)
New York (3004)
North Carolina (1466)
North Dakota (8)
Northern California (5576)
Ohio (337)
Oklahoma (21)
Oregon (41)
Pennsylvania (2303)
Puerto Rico (24)
Rhode Island (48)
South America (1109)
South Carolina (67)
South Dakota (1)
Southern California (4438)
Tennessee (177)
Texas (1755)
United States (40393)
Utah (340)
Vermont (1)
Virginia (264)
Washington D.C. (81)
Washington State (927)
West Virginia (4)
Wisconsin (111)
Wyoming (2)
722,302 Results for "santen inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Sydnexis Announces UK Approval of Ryjunea® by Partner Santen to Slow Progression of Childhood Myopia
November 7, 2025
·
1 min read
Deals
Harrow Acquires Santen’s Branded Ophthalmic Portfolio
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the signing of agreements with affiliates of Santen Pharmaceutical Co., Ltd. (“Santen”) under which Harrow will acquire certain U.S. and Canadian commercial rights for the following branded products from Santen:
July 18, 2023
·
15 min read
Santen Agrees to Licensing Agreements and Asset Transfer for its Pharmaceutical Products in North America
Santen Pharmaceutical Co., Ltd. announced that it has signed licensing agreements and an asset transfer agreement with two U.S. companies.
July 18, 2023
·
2 min read
Santen Announces Health Canada Approval for Cationorm® Plus to Relieve the Symptoms of Dry Eye and Ocular Allergy
Santen Canada Inc., a subsidiary of Santen Pharmaceutical Co., Ltd. (Santen), today announced the approval of Cationorm® Plus by Health Canada.
October 6, 2022
·
5 min read
Press Releases
Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema
November 8, 2024
·
7 min read
Biotech Bay
Santen’s Verkazia® (Cyclosporine Ophthalmic Emulsion) 0.1% Now Available for the Treatment of Vernal Keratoconjunctivitis in Children and Adults in the United States
Santen’s Verkazia ® (Cyclosporine Ophthalmic Emulsion) 0.1% Now Available for the Treatment of Vernal Keratoconjunctivitis in Children and Adults in the United States.
May 2, 2022
·
4 min read
Press Releases
BioSyent to Acquire Oral Science Inc.
February 9, 2026
·
10 min read
Press Releases
Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock
February 18, 2026
·
5 min read
Press Releases
Axogen, Inc. to Participate in Multiple Upcoming March 2026 Investor Conferences
February 17, 2026
·
1 min read
FDA
Santen and UBE Received FDA Approval for OMLONTI® (Omidenepag Isopropyl Ophthalmic Solution) 0.002% for the Reduction of Elevated Intraocular Pressure in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension
Santen Inc., the U.S. subsidiary of Santen Pharmaceutical Co., Ltd. (Santen), and UBE Corporation (UBE) today announced that the U.S. Food and Drug Administration (FDA) has approved OMLONTI® (omidenepag isopropyl ophthalmic solution) 0.002% eye drops for the reduction of elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension.
September 26, 2022
·
7 min read
1 of 72,231
Next
